- \n
- Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers<\/i><\/li>\n
- Live Debut at Nasdaq MarketSite, New York City \u2014 April 16, 2026, 12:00\u20132:00 PM Eastern<\/i><\/li>\n
- Public Demonstrations at AACR 2026, San Diego \u2014 Booth 5054, April 17\u201322<\/i><\/li>\n<\/ul>\n
DALLAS–(BUSINESS WIRE<\/a>)–
\nLantern Pharma Inc. (Nasdaq: LTRN) (\u201cLantern\u201d or the \u201cCompany\u201d), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai<\/a><\/b>\u2014 the world\u2019s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development \u2014 is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai<\/a><\/b>, spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform\u2019s commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026<\/b>, and public demonstrations at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego at Booth 5054 during April 17\u201322<\/b>.<\/p>\nwithZeta.ai<\/a> is the next generation of the AI platform technologies from RADR\u00ae<\/sup>, an oncology focused experimental biology and molecular analysis platform Lantern Pharma has built for its own cancer programs \u2014 and is now making available to the broader drug discovery and research communities. For rare cancer patients who cannot afford to wait decades for new therapies, it is an AI for good \u2014 one with a genuine and immediate opportunity to change the pace, cost, productivity and precision of drug discovery.<\/p>\n
The Nasdaq MarketSite Debut \u2014 April 16, 2026<\/b><\/p>\n
\nOn Thursday, April 16, 2026 from 12:00 PM to 2:00 PM Eastern, Lantern Pharma will host an exclusive live demonstration of withZeta.ai<\/a> at Nasdaq MarketSite in New York City \u2014 one of the world\u2019s most recognized venues for presenting innovation to the financial and biotech investment community. The event will bring together 25 of the biotech industry\u2019s leading investors, analysts, and media professionals for a first-hand experience of the platform in action, including live multi-agentic research workflows, real-time multi-database querying, development of a molecule for a rare cancer indication and also highlight the full commercial subscription model and opportunity.<\/p>\n
\nFor Lantern shareholders, the Nasdaq MarketSite event represents a significant milestone: the Company presenting a commercially deployed, revenue-generating AI platform directly to the institutional and analytical community that covers and invests in the biotech sector. The event is by invitation only. Investors and analysts seeking to attend or schedule a one-on-one demonstration should contact ir@lanternpharma.com<\/a>.<\/p>\n
withZeta.ai at AACR 2026 \u2014 Booth 5054, San Diego<\/b><\/p>\n
\nFrom April 17 through April 22, 2026, Lantern Pharma will showcase withZeta.ai<\/a> at the American Association for Cancer Research Annual Meeting in San Diego \u2014 one of the world\u2019s premier oncology research and industry gatherings, attended by leading cancer researchers, clinicians, biopharma executives, and potential enterprise partners and customers. Attendees can experience the platform live at Booth 5054 across rare cancer characterization, drug discovery, combination therapy exploration, clinical trial development and analysis, and molecular optimization including for CNS related cancers.<\/p>\n
\nAACR 2026 marks withZeta.ai<\/a>\u2019s first major public debut before the global oncology research and drug development community \u2014 the precise audience the platform was built to serve and from which its commercial subscriber base will grow. Researchers, clinicians, and drug developers are invited to visit Booth 5054 and experience firsthand what an AI co-scientist purpose-built for rare cancers can accomplish.<\/p>\n
The Co-Scientist AI Platform \u2014 Now Live<\/b><\/p>\n
withZeta.ai<\/a> is positioned as a force multiplier for the entire biomedical and drug development community \u2014 enabling investigators, R&D teams, biopharma companies, and global pharma enterprises to conduct in minutes or hours the research that once took weeks, months and years. Powered by a multi-agentic, multi-tool architecture and grounded in Lantern Pharma\u2019s proprietary rare cancer ontology and knowledge-base spanning 438 cancer types, the platform simultaneously queries clinical trial databases, curated rare cancer knowledge bases, scientific literature libraries, and molecular databases \u2014 reasoning across all of them to deliver hardened, actionable insights.<\/p>\n
\nThe platform offers three research modes \u2014 Explorer, Investigator, and Reporter \u2014 allowing users to move seamlessly from rapid hypothesis generation through deep systematic evidence synthesis to structured, publication-ready documentation. Specialized capabilities include blood-brain barrier penetration prediction via PredictBBB.ai at 94.1% accuracy and generative molecular design via the ether0 24-billion parameter AI model.<\/p>\n
\nUnlike general-purpose AI tools, withZeta.ai<\/a> is grounded in a proprietary oncology ontology and knowledge-base that maps disease synonyms, links biomarkers to therapeutic responses, and builds hierarchical relationships between cancer subtypes \u2014 a structural advantage that took a decade to build and cannot be replicated.<\/p>\n
\u201cwithZeta.ai<\/a> was forged in the crucible of real rare cancer drug development \u2014 not built in a vacuum. Every insight, every ontology, every agent and function within the platform reflects real world work at Lantern Pharma across three drugs now in precision oncology clinical trials, more than 100 patients dosed and studied, and 12 FDA designations earned across orphan, pediatric rare disease, and fast track classifications for Lantern. Our RADR\u00ae AI platform taught us what it means to build AI that actually works in the most challenging corners of oncology. withZeta.ai<\/a> is that knowledge, scaled and made available to the world. For the first time, any researcher anywhere can have a tireless, always-on AI co-scientist in their corner \u2014 one that brings the collective intelligence of millions of publications, hundreds of thousands of clinical trials, and a decade of rare cancer expertise to every single question they ask. That is a force multiplier the drug development community has never had before. And for rare cancer patients who are running out of time, it cannot come soon enough.\u201d
\n
<\/i>\u2014Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.<\/b><\/p>\nThe Commercial Opportunity \u2014 Subscriptions Now Open<\/b><\/p>\n
withZeta.ai<\/a> is now commercially available with a fully enabled subscription payment model serving the full spectrum of the biomedical research and drug development community \u2014 and representing a new, non-dilutive revenue stream for Lantern Pharma shareholders. Subscription tiers include:<\/p>\n
- \n
- Introductory Access: <\/b>Entry-level access that puts a powerful AI co-scientist in the hands of any researcher or clinician immediately \u2014 with no barriers to getting started and no prior AI expertise required.\n<\/li>\n
- Academic Subscription: <\/b>Expanded research depth and multi-database access for academic institutions, independent investigators, and non-commercial researchers \u2014 compressing weeks of literature review into hours.\n<\/li>\n
- Commercial Subscription: <\/b>Full-platform capabilities for biotech and pharmaceutical professionals, drug discovery teams, clinical trial designers, and enterprise R&D organizations \u2014 including priority access to Lantern\u2019s proprietary RADR\u00ae genomic response database and enterprise partnership development opportunities.\n<\/li>\n<\/ul>\n
\nSubscriptions are available immediately at withzeta.ai<\/a>. Enterprise and technology partnership inquiries may be directed to ir@lanternpharma.com<\/a>. Lantern Pharma is in active discussions with technology and system integrators serving the enterprise needs of cancer centers, research organizations and large biopharma companies.<\/p>\n
The Market Opportunity \u2014 Democratizing Rare Cancer Research at Scale<\/b><\/p>\n
\nThe imperative driving withZeta.ai<\/a> is both scientific and economic. Drug development costs approximately $1 to $2 billion regardless of target population size. For the hundreds of distinct rare cancer types affecting fewer than 200,000 patients each in the United States, these development costs cannot be recouped through traditional commercial returns \u2014 creating a systematic abandonment of patient populations that desperately need therapeutic options. withZeta.ai<\/a> directly addresses this market failure by dramatically compressing the cost and time of the research and hypothesis-generation phases that precede expensive wet lab work and clinical trials, shifting the economics of rare cancer drug development in favor of the patients who need it most.<\/p>\n
\u201cThe commercial opportunity in front of withZeta.ai<\/a> is as large as it is urgent. The global AI drug discovery market is projected to exceed $15 billion by 2030 \u2014 with oncology commanding the largest therapeutic share \u2014 and rare cancers remain the most underserved, highest-urgency segment within it. withZeta.ai<\/a> enters this market as a fully deployed, subscription-enabled, revenue-generating platform with a proprietary ontological foundation that general-purpose AI tools simply cannot replicate. For biotech investors and corporate development professionals, this is a platform already embedded in the drug development workflow \u2014 generating real insights, accelerating real programs, and creating a scalable, defensible, non-dilutive revenue stream for Lantern shareholders. We are inviting the investment community to experience it directly \u2014 at Nasdaq MarketSite on April 16th and at AACR Booth 5054 in San Diego. Rare cancer patients should not have to wait decades for insights, therapies, and thoughtful trials. Our platform \u2014 an AI for good \u2014 has a real and immediate opportunity to change that dynamic.\u201d
\n
<\/i>\u2014Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.<\/b><\/p>\n\nThe global AI drug discovery and development market is projected to grow at a compound annual growth rate exceeding 30% through 2030, with the oncology segment commanding the largest therapeutic area share. withZeta.ai<\/a>\u2019s scalable subscription model \u2014 spanning individual researchers through global pharma enterprises \u2014 is designed to capture meaningful and growing revenue across every segment of this market as the migration of scientific knowledge work to AI co-scientists accelerates.<\/p>\n
Experience withZeta.ai \u2014 Event & Access Details<\/b><\/p>\n
Nasdaq MarketSite Event:
\n
<\/b>Date: <\/b>Thursday, April 16, 2026
\n
Time: <\/b>12:00 PM \u2013 2:00 PM Eastern
\n
Location: <\/b>Nasdaq MarketSite, New York City
\n
Attendance: <\/b>By invitation only \u2014 contact ir@lanternpharma.com<\/a> to request access<\/p>\nAACR Annual Meeting 2026:
\n
<\/b>Dates: <\/b>April 17\u201322, 2026
\n
Location: <\/b>San Diego Convention Center, San Diego, California
\n
Booth: <\/b>5054
\n
Platform Access: <\/b>Live demonstrations available throughout the conference<\/p>\nSubscribe Now: <\/b>withzeta.ai
\n<\/a>
Investor Inquiries: <\/b>ir@lanternpharma.com<\/a> | +1-972-277-1136<\/p>\nABOUT LANTERN PHARMA INC.<\/b><\/p>\n
\nLantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR\u00ae platform to transform the development of cancer therapies. Lantern\u2019s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin\/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern\u2019s wholly owned CNS-focused subsidiary. withZeta.ai<\/a>, Lantern\u2019s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.<\/p>\n
ABOUT withZeta.ai<\/b><\/p>\n
withZeta.ai<\/a> is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done. Knowledge work in oncology is migrating to AI co-scientists \u2014 autonomous systems that investigate, reason, and synthesize across the full breadth of scientific evidence. withZeta.ai<\/a> is that co-scientist: purpose-built for the biology, economics, and urgency of rare cancer drug development, and accessible to any researcher, anywhere. Built by Lantern Pharma (Nasdaq: LTRN). Learn more and subscribe at withzeta.ai<\/a>.<\/p>\n
FORWARD-LOOKING STATEMENTS<\/b><\/p>\n
\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR\u00ae platform and withZeta.ai<\/a> platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; the planned commercialization of our AI platforms including withZeta.ai<\/a> and the expected market opportunity for AI co-scientist platforms; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR\u00ae platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.<\/p>\n
\nAny statements that are not statements of historical fact (including, without limitation, statements that use words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cmodel,\u201d \u201cobjective,\u201d \u201caim,\u201d \u201cupcoming,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR\u00ae AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, (vii) the risk that our AI platform commercialization efforts, including withZeta.ai<\/a>, may not generate the anticipated revenue or achieve the expected market adoption, and (viii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.<\/p>\n
\nYou may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com<\/a> or on the SEC\u2019s website at www.sec.gov<\/a>. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260414869501\/en\/<\/a><\/span><\/p>\n
INVESTOR RELATIONS CONTACT
\n<\/b>
Lantern Pharma Inc. ir@lanternpharma.com<\/a> +1-972-277-1136 ir.lanternpharma.com<\/a><\/p>\nKEYWORDS:<\/b> Texas United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Software Research Pharmaceutical Oncology Data Management Technology Artificial Intelligence Health Technology Science Biotechnology Other Science Health<\/p>\n
- Academic Subscription: <\/b>Expanded research depth and multi-database access for academic institutions, independent investigators, and non-commercial researchers \u2014 compressing weeks of literature review into hours.\n<\/li>\n
- Live Debut at Nasdaq MarketSite, New York City \u2014 April 16, 2026, 12:00\u20132:00 PM Eastern<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260414869501\/en\/1827644\/3\/Lanternlogo_square.jpg\")
<\/td>\n<\/tr>\n